JP2010529026A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010529026A5 JP2010529026A5 JP2010510385A JP2010510385A JP2010529026A5 JP 2010529026 A5 JP2010529026 A5 JP 2010529026A5 JP 2010510385 A JP2010510385 A JP 2010510385A JP 2010510385 A JP2010510385 A JP 2010510385A JP 2010529026 A5 JP2010529026 A5 JP 2010529026A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- booster
- human
- peptide
- adjuvant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 43
- 239000002671 adjuvant Substances 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 238000002347 injection Methods 0.000 claims 8
- 239000007924 injection Substances 0.000 claims 8
- 206010006187 Breast cancer Diseases 0.000 claims 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000014509 gene expression Effects 0.000 claims 3
- 230000036039 immunity Effects 0.000 claims 3
- 230000002055 immunohistochemical effect Effects 0.000 claims 3
- 230000001681 protective effect Effects 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 108700020302 erbB-2 Genes Proteins 0.000 claims 2
- 238000011156 evaluation Methods 0.000 claims 2
- 238000007901 in situ hybridization Methods 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 210000000265 leukocyte Anatomy 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 101150054472 HER2 gene Proteins 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- 238000011081 inoculation Methods 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94152407P | 2007-06-01 | 2007-06-01 | |
| US60/941,524 | 2007-06-01 | ||
| PCT/US2008/060044 WO2008150577A1 (en) | 2007-06-01 | 2008-04-11 | Vaccine for the prevention of breast cancer relapse |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014138567A Division JP6097724B2 (ja) | 2007-06-01 | 2014-07-04 | 乳癌再発の予防のためのワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010529026A JP2010529026A (ja) | 2010-08-26 |
| JP2010529026A5 true JP2010529026A5 (enExample) | 2011-04-28 |
| JP5635399B2 JP5635399B2 (ja) | 2014-12-03 |
Family
ID=40094045
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010510385A Expired - Fee Related JP5635399B2 (ja) | 2007-06-01 | 2008-04-11 | 乳癌再発の予防のためのワクチン |
| JP2014138567A Expired - Fee Related JP6097724B2 (ja) | 2007-06-01 | 2014-07-04 | 乳癌再発の予防のためのワクチン |
| JP2016211150A Pending JP2017071607A (ja) | 2007-06-01 | 2016-10-28 | 乳癌再発の予防のためのワクチン |
| JP2018153050A Expired - Fee Related JP7072467B2 (ja) | 2007-06-01 | 2018-08-16 | 乳癌再発の予防のためのワクチン |
| JP2020161232A Pending JP2021001218A (ja) | 2007-06-01 | 2020-09-25 | 乳癌再発の予防のためのワクチン |
| JP2022068170A Pending JP2022095926A (ja) | 2007-06-01 | 2022-04-18 | 乳癌再発の予防のためのワクチン |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014138567A Expired - Fee Related JP6097724B2 (ja) | 2007-06-01 | 2014-07-04 | 乳癌再発の予防のためのワクチン |
| JP2016211150A Pending JP2017071607A (ja) | 2007-06-01 | 2016-10-28 | 乳癌再発の予防のためのワクチン |
| JP2018153050A Expired - Fee Related JP7072467B2 (ja) | 2007-06-01 | 2018-08-16 | 乳癌再発の予防のためのワクチン |
| JP2020161232A Pending JP2021001218A (ja) | 2007-06-01 | 2020-09-25 | 乳癌再発の予防のためのワクチン |
| JP2022068170A Pending JP2022095926A (ja) | 2007-06-01 | 2022-04-18 | 乳癌再発の予防のためのワクチン |
Country Status (16)
| Country | Link |
|---|---|
| US (6) | US8222214B2 (enExample) |
| EP (2) | EP2722336A1 (enExample) |
| JP (6) | JP5635399B2 (enExample) |
| KR (5) | KR20210097209A (enExample) |
| CN (2) | CN105816867A (enExample) |
| AU (1) | AU2008260399C1 (enExample) |
| CA (1) | CA2687368C (enExample) |
| CY (1) | CY1114912T1 (enExample) |
| DK (1) | DK2162149T3 (enExample) |
| ES (1) | ES2445399T3 (enExample) |
| HR (1) | HRP20140102T1 (enExample) |
| MX (1) | MX2009012858A (enExample) |
| PL (1) | PL2162149T3 (enExample) |
| PT (1) | PT2162149E (enExample) |
| SI (1) | SI2162149T1 (enExample) |
| WO (1) | WO2008150577A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8945573B2 (en) | 2005-09-08 | 2015-02-03 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Targeted identification of immunogenic peptides |
| KR20210097209A (ko) * | 2007-06-01 | 2021-08-06 | 더 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신, 인코포레이티드 | 유방암 재발 예방용 백신 |
| EP2355843B8 (en) | 2008-12-10 | 2017-08-02 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Vaccine for the prevention of breast cancer recurrence |
| CA2864841C (en) | 2012-02-17 | 2020-07-07 | Keith L. Knutson | Methods and materials for generating cd8+ t cells having the ability to recognize cancer cells expressing a her2/neu polypeptide |
| US10028918B2 (en) | 2012-05-08 | 2018-07-24 | Albert Einstein College Of Medicine, Inc. | Nanoparticle delivery vehicle for S-nitroso-N-acetyl cysteine and uses thereof |
| EP2854843A4 (en) | 2012-05-31 | 2016-06-01 | Sorrento Therapeutics Inc | ANTIGEN-BINDING PROTEINS FOR BINDING PD-L1 |
| US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
| JP2014169283A (ja) * | 2013-02-05 | 2014-09-18 | Nitto Denko Corp | 粘膜投与用ワクチン組成物 |
| CN103961696A (zh) * | 2013-02-05 | 2014-08-06 | 日东电工株式会社 | 经皮给予用疫苗组合物 |
| EP2777711A1 (en) | 2013-03-11 | 2014-09-17 | Icon Genetics GmbH | Her2/Neu cancer vaccine |
| CN104513293A (zh) * | 2013-09-26 | 2015-04-15 | 深圳信立泰药业股份有限公司 | 一种多肽疫苗的盐及其制备方法和含有该盐的药物制品 |
| WO2015066020A1 (en) * | 2013-10-28 | 2015-05-07 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Methods of monitoring immune responses |
| US10434152B2 (en) * | 2014-02-20 | 2019-10-08 | Wayne State University | HER2 antigenic polypeptide compositions, and methods for their use in treatment and prevention of carcinomas |
| EA037855B1 (ru) | 2016-01-29 | 2021-05-27 | Сорренто Терапьютикс, Инк. | Полностью человеческое антитело класса igg, связывающееся с эпитопом pd-l1 |
| EP3463438B1 (en) * | 2016-05-31 | 2022-04-06 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Vaccine therapy for treatment of endometrial and ovarian cancer |
| WO2020086412A1 (en) * | 2018-10-21 | 2020-04-30 | Slsg Limited Llc | Combination immunotherapy for treatment of triple-negative breast cancer |
| EP4336187A4 (en) | 2021-05-04 | 2025-06-11 | Aston Sci. Inc. | ANTI-HER2 VACCINE COMPOSITION |
| KR20230017640A (ko) | 2021-07-28 | 2023-02-06 | 주식회사 애스톤사이언스 | Her2 백신 조성물 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4744984A (en) | 1985-10-08 | 1988-05-17 | Vetrepharm Research, Inc. | Antiviral immunotherapeutic agent and preparation thereof |
| WO1990014357A1 (en) | 1989-05-19 | 1990-11-29 | Genentech, Inc. | Her2 extracellular domain |
| US7252829B1 (en) * | 1998-06-17 | 2007-08-07 | Idm Pharma, Inc. | HLA binding peptides and their uses |
| US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| EP0793501A4 (en) | 1994-12-14 | 2000-05-03 | Scripps Research Inst | IN VIVO ACTIVATION OF TUMOR SPECIFIC CYTOTOXIC T CELLS |
| US6514942B1 (en) | 1995-03-14 | 2003-02-04 | The Board Of Regents, The University Of Texas System | Methods and compositions for stimulating T-lymphocytes |
| US20030022820A1 (en) | 1995-12-14 | 2003-01-30 | Linda A. Sherman | In vivo activation of tumor-specific cytotoxic t cells |
| US5891432A (en) | 1997-07-29 | 1999-04-06 | The Immune Response Corporation | Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same |
| WO2001008636A2 (en) * | 1999-08-03 | 2001-02-08 | The Ohio State University | Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein |
| EP1216055A2 (en) * | 1999-09-30 | 2002-06-26 | Corixa Corporation | Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
| US6602510B1 (en) | 2000-04-05 | 2003-08-05 | Epimmune Inc. | HLA class I A2 tumor associated antigen peptides and vaccine compositions |
| US20030224036A1 (en) | 1999-12-13 | 2003-12-04 | Fikes John D | Hla class I a2 tumor associated antigen peptides and vaccine compositions |
| US20070098776A1 (en) | 1999-12-13 | 2007-05-03 | Fikes John D | HLA class I A2 tumor associated antigen peptides and vaccine compositions |
| US20040121946A9 (en) * | 2000-12-11 | 2004-06-24 | John Fikes | Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions |
| US7037501B2 (en) * | 2001-01-04 | 2006-05-02 | Regents Of The University Of Minnesota | Myostatin immnoconjugate |
| AU2002318186A1 (en) * | 2001-07-03 | 2003-01-21 | Lexicon Genetics Incorporated | Novel human kielin-like proteins and polynucleotides encoding the same |
| AU2002354644C1 (en) | 2001-07-10 | 2009-04-30 | Corixa Corporation | Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres |
| US20030049253A1 (en) | 2001-08-08 | 2003-03-13 | Li Frank Q. | Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines |
| EP1482963A4 (en) | 2002-03-08 | 2010-06-09 | Univ Texas | CONTROLLED MODULATION OF THE AMINO ACID SIDE CHAIN LENGTH OF PEPTIDE ANTIGEN |
| KR100555211B1 (ko) * | 2002-07-16 | 2006-03-03 | 주식회사 팬제노믹스 | 항암효과를 갖는 Ｈｅｒ-２/ｎｅｕ ＤＮＡ 백신 |
| EP1553966B1 (en) * | 2002-10-03 | 2012-08-01 | Wyeth Holdings Corporation | Fusion peptides comprising the human papillomavirus e7 and e6 polypeptides and immunogenic compositions thereof |
| WO2004069866A1 (en) | 2003-02-10 | 2004-08-19 | Autogen Research Pty Ltd | Therapeutic molecules |
| JP2007524654A (ja) | 2003-06-06 | 2007-08-30 | エイジェニックス インコーポレイテッド | 癌ワクチン中のアジュバントとしてのラクトフェリン |
| WO2005014634A1 (en) * | 2003-08-12 | 2005-02-17 | Agt Biosciences Limited | A gene and uses therefor |
| US20050215501A1 (en) | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
| US20060275777A1 (en) | 2005-06-03 | 2006-12-07 | Waelti Ernst R | Novel strategies for protein vaccines |
| KR20210097209A (ko) | 2007-06-01 | 2021-08-06 | 더 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신, 인코포레이티드 | 유방암 재발 예방용 백신 |
-
2008
- 2008-04-11 KR KR1020217023573A patent/KR20210097209A/ko not_active Abandoned
- 2008-04-11 ES ES08745615.8T patent/ES2445399T3/es active Active
- 2008-04-11 DK DK08745615.8T patent/DK2162149T3/da active
- 2008-04-11 MX MX2009012858A patent/MX2009012858A/es active IP Right Grant
- 2008-04-11 SI SI200831143T patent/SI2162149T1/sl unknown
- 2008-04-11 EP EP13191663.7A patent/EP2722336A1/en not_active Ceased
- 2008-04-11 WO PCT/US2008/060044 patent/WO2008150577A1/en not_active Ceased
- 2008-04-11 KR KR1020207004398A patent/KR102283639B1/ko not_active Expired - Fee Related
- 2008-04-11 PT PT87456158T patent/PT2162149E/pt unknown
- 2008-04-11 KR KR1020157007937A patent/KR101863534B1/ko not_active Expired - Fee Related
- 2008-04-11 CA CA2687368A patent/CA2687368C/en active Active
- 2008-04-11 CN CN201610201242.6A patent/CN105816867A/zh active Pending
- 2008-04-11 HR HRP20140102AT patent/HRP20140102T1/hr unknown
- 2008-04-11 CN CN200880018401A patent/CN101678093A/zh active Pending
- 2008-04-11 AU AU2008260399A patent/AU2008260399C1/en not_active Ceased
- 2008-04-11 JP JP2010510385A patent/JP5635399B2/ja not_active Expired - Fee Related
- 2008-04-11 PL PL08745615T patent/PL2162149T3/pl unknown
- 2008-04-11 KR KR1020187014920A patent/KR102079921B1/ko not_active Expired - Fee Related
- 2008-04-11 EP EP08745615.8A patent/EP2162149B1/en active Active
- 2008-04-11 US US12/602,214 patent/US8222214B2/en not_active Expired - Fee Related
- 2008-04-11 KR KR1020097027587A patent/KR101572474B1/ko not_active Expired - Fee Related
-
2012
- 2012-06-27 US US13/534,550 patent/US8796220B2/en active Active
-
2014
- 2014-01-30 CY CY20141100076T patent/CY1114912T1/el unknown
- 2014-07-04 JP JP2014138567A patent/JP6097724B2/ja not_active Expired - Fee Related
- 2014-07-09 US US14/327,224 patent/US9370560B2/en not_active Expired - Fee Related
-
2016
- 2016-10-28 JP JP2016211150A patent/JP2017071607A/ja active Pending
-
2018
- 2018-03-05 US US15/912,156 patent/US10842856B2/en not_active Expired - Fee Related
- 2018-08-16 JP JP2018153050A patent/JP7072467B2/ja not_active Expired - Fee Related
-
2020
- 2020-09-25 JP JP2020161232A patent/JP2021001218A/ja active Pending
- 2020-10-21 US US17/076,635 patent/US20220347281A1/en not_active Abandoned
-
2022
- 2022-01-12 US US17/574,178 patent/US20220241389A1/en not_active Abandoned
- 2022-04-18 JP JP2022068170A patent/JP2022095926A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010529026A5 (enExample) | ||
| HRP20140102T1 (hr) | Cjepivo za prevenciju relapsa raka dojke | |
| Wallach et al. | Advances in the treatment of neuromyelitis optica spectrum disorder | |
| JP2014114288A5 (enExample) | ||
| HRP20190799T1 (hr) | Imunocitokini na bazi il-15 i sushi domene il-15r alfa | |
| JP2016530323A5 (enExample) | ||
| JP2015508774A5 (enExample) | ||
| Melo et al. | Golimumab (anti-TNF monoclonal antibody): where we stand today | |
| JP2012102122A5 (enExample) | ||
| CN108392633A (zh) | Pcsk9抑制剂在恶性肿瘤免疫治疗中的应用 | |
| US9884098B2 (en) | Multivalent breast cancer vaccine | |
| JP2015517511A5 (enExample) | ||
| JP2014500278A5 (enExample) | ||
| JP2015526446A5 (enExample) | ||
| AU2025202861A1 (en) | Vaccine compositions and methods for restoring NKG2D pathway function against cancers | |
| JP2014500278A (ja) | 二重特異性ｓｃＦｖコンジュゲートの投薬量および投与 | |
| TW201043698A (en) | Enhanced immune response in avian species | |
| JP2024001125A (ja) | Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 | |
| CN106540256A (zh) | 环二核苷酸-脂质体偶联单克隆抗体在抗肿瘤中的应用 | |
| JP2018522041A (ja) | 改変酵母−ブラキュリー免疫療法組成物 | |
| JP2015172060A5 (enExample) | ||
| CN103768595A (zh) | 唑来膦酸佐剂及含唑来膦酸佐剂的疫苗 | |
| JP2009544610A5 (enExample) | ||
| JP2015516980A5 (enExample) | ||
| US20200000899A1 (en) | Pharmaceutical composition for use in the treatment of cancer |